BRIEF-SCYNEXIS Receives FDA Qualified Infectious Disease Product And Fast Track Designations For SCY-247

Reuters

Jan 21

BRIEF-SCYNEXIS Receives FDA Qualified Infectious Disease Product And <a href="https://laohu8.com/S/FTRK">Fast Track</a> Designations For SCY-247

Jan 21 (Reuters) - SCYNEXIS Inc SCYX.O:

SCYNEXIS RECEIVES FDA QUALIFIED INFECTIOUS DISEASE PRODUCT (QIDP) AND FAST TRACK DESIGNATIONS FOR SCY-247
SCYNEXIS INC - TO INITIATE PHASE 1 AND 2 STUDIES OF SCY-247 IN 2026
SCYNEXIS INC - QIDP DESIGNATION ENSURES 10 YEARS MARKET EXCLUSIVITY FOR SCY-247

Source text: ID:nGNX9wStQ6

Further company coverage: SCYX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2605410229"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605410229\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605410229?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605410229","market":"nz","top_or_hot":-1,"title":"BRIEF-SCYNEXIS Receives FDA Qualified Infectious Disease Product And Fast Track Designations For SCY-247","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-SCYNEXIS Receives FDA Qualified Infectious Disease Product And <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designations For SCY-247</title></head><body><p><span>Jan 21 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SCYX\">SCYNEXIS Inc</a> <span>SCYX.O</span>:</p><ul><li><p>SCYNEXIS RECEIVES FDA QUALIFIED INFECTIOUS DISEASE PRODUCT (QIDP) AND FAST TRACK DESIGNATIONS FOR SCY-247</p></li><li><p>SCYNEXIS INC - TO INITIATE PHASE 1 AND 2 STUDIES OF SCY-247 IN 2026</p></li><li><p>SCYNEXIS INC - QIDP DESIGNATION ENSURES 10 YEARS MARKET EXCLUSIVITY FOR SCY-247</p></li></ul><p>Source text: <span>ID:nGNX9wStQ6</span></p><p>Further company coverage: <span>SCYX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-SCYNEXIS Receives FDA Qualified Infectious Disease Product And Fast Track Designations For SCY-247</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-SCYNEXIS Receives FDA Qualified Infectious Disease Product And Fast Track Designations For SCY-247\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-21 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-SCYNEXIS Receives FDA Qualified Infectious Disease Product And <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designations For SCY-247</title></head><body><p><span>Jan 21 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SCYX\">SCYNEXIS Inc</a> <span>SCYX.O</span>:</p><ul><li><p>SCYNEXIS RECEIVES FDA QUALIFIED INFECTIOUS DISEASE PRODUCT (QIDP) AND FAST TRACK DESIGNATIONS FOR SCY-247</p></li><li><p>SCYNEXIS INC - TO INITIATE PHASE 1 AND 2 STUDIES OF SCY-247 IN 2026</p></li><li><p>SCYNEXIS INC - QIDP DESIGNATION ENSURES 10 YEARS MARKET EXCLUSIVITY FOR SCY-247</p></li></ul><p>Source text: <span>ID:nGNX9wStQ6</span></p><p>Further company coverage: <span>SCYX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUA45C3JQ:1","article_id":"2605410229","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605410229","pubTimestamp":1769000519,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-SCYNEXIS Receives FDA Qualified Infectious Disease Product And Fast Track Designations For SCY-247Jan 21 (Reuters) - SCYNEXIS Inc SCYX.O:SCYNEXIS RECEIVES FDA QUALIFIED INFECTIOUS DISEASE PRODUC","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SCYX":"SCYNEXIS Inc"},"translate_title":"简介-SCYNEXIS获得FDA合格传染病产品和SCY-247快速通道指定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCYX":0.9},"content_text":"BRIEF-SCYNEXIS Receives FDA Qualified Infectious Disease Product And Fast Track Designations For SCY-247Jan 21 (Reuters) - SCYNEXIS Inc SCYX.O:SCYNEXIS RECEIVES FDA QUALIFIED INFECTIOUS DISEASE PRODUCT (QIDP) AND FAST TRACK DESIGNATIONS FOR SCY-247SCYNEXIS INC - TO INITIATE PHASE 1 AND 2 STUDIES OF SCY-247 IN 2026SCYNEXIS INC - QIDP DESIGNATION ENSURES 10 YEARS MARKET EXCLUSIVITY FOR SCY-247Source text: ID:nGNX9wStQ6Further company coverage: SCYX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}